Drug profile

The FDA adverse-event record for Glucosamine Chondroitin

38 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Chondroitin. See the species affected, top reactions, and outcomes below.

38
adverse-event reports
23.7%
death-coded share
Dog
most-reported species
9
Abnormal radiograph finding - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
38
Total Reports
9
Deaths Reported
23.7%
Death Rate

Active Ingredients

Glucosamine Chondroitin

Administration Routes

OralUnknown

Species Affected

Dog 33
Cat 5

Most Affected Breeds

Dog (unknown) 4
Retriever - Labrador 4
Retriever - Golden 4
Domestic Shorthair 4
Terrier - Bull - American Pit 3
Mastiff 2
Pointing Dog - Hungarian Short-haired (Vizsla) 2
Shepherd Dog - German 2
Mixed (Dog) 1
Crossbred Canine/dog 1

Most Reported Reactions

Abnormal radiograph finding 9
Lethargy (see also Central nervous system depression in Neurological) 8
Diarrhoea 7
Death by euthanasia 7
Vomiting 6
Elevated alanine aminotransferase (ALT) 5
Anorexia 4
Weight loss 4
Other abnormal test result NOS 4
Ataxia 4
Limb weakness 4
Abnormal cytology 4

Outcome Breakdown

Ongoing
15 (39.5%)
Recovered/Normal
7 (18.4%)
Outcome Unknown
7 (18.4%)
Euthanized
7 (18.4%)
Died
2 (5.3%)

Glucosamine Chondroitin Adverse Event Insights

38 reports name Glucosamine Chondroitin; 9 recorded a death outcome (23.7% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Chondroitin. Administration routes: Oral, Unknown.

By species: Dog (33 reports), Cat (5 reports). By breed: Dog (unknown) (4), Retriever - Labrador (4), Retriever - Golden (4).

Leading clinical signs: Abnormal radiograph finding (9), Lethargy (see also Central nervous system depression in Neurological) (8), Diarrhoea (7), Death by euthanasia (7). Outcome, 38 coded reports: Ongoing leads at 39.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.